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Abstract  
Human  flavin-­containing  monooxygenase  3  (hFMO3)  is  a  drug  metabolising  enzyme  that  
oxygenates  many  drugs  and  xenobiotics  in  the  liver.  This  enzyme  is  also  known  to  exhibit  
single  nucleotide  polymorphisms  (SNPs)  that  can  alter  the  rates  of  monooxygenation  of  
therapeutic  agents.  The  purpose  of  this  study  was  to  investigate  the  effect  of  the  three  
common  polymorphic  variants  of  hFMO3  (V257M,  E158K  and  E308G)  on  the  metabolism  
and  clearance  of  3  structurally  similar  compounds:  tamoxifen  (breast  cancer  medication),  
clomiphene   (infertility   medication)   and   GSK5182   (anti-­diabetic   lead   molecule).   For  
GSK5182,  none  of  the  three  variants  showed  any  significant  differences  in  its  metabolism  
when  compared  to  the  wild-­type  enzyme.  In  the  case  of  clomiphene,  two  of  the  variants,  
V257M   and   E308G,   exhibited   a   significant   increase   in   all   the   kinetic   parameters  
measured  with  nearly  two  times  faster  clearance.  Finally,  for  tamoxifen  a  mixed  behavior  
was  observed;;  E158K  variant  showed  a  significantly  higher  clearance  compared  to  the  
wild-­type  whereas  V257M  mutation  had  the  opposite  effect.  Overall,   the  data  obtained  
demonstrate  that  there  is  no  direct  correlation  between  the  SNPs  and  the  metabolism  of  
these   three   hFMO3   substrates.   The   metabolic   capacity   is   both   variant-­   as   well   as  
substrate-­dependent   and   therefore   when   testing   new   drugs   or   administering   already  
approved  therapies  these  differences  should  be  taken  into  consideration.    
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Introduction  
Over   the   last   few   years   it   has   become   increasingly   clear   that   there   are   significant  
differences  in  drug  metabolism  related  to  polymorphisms  of  drug  metabolising  enzymes  
including  the  hepatic  hFMO3  (Human  flavin-­containing  monooxygenase  isoform  3)  [1-­5].  
This   enzyme   is   known   to   be   highly   polymorphic   with  more   than   20   single   nucleotide  
polymorphisms   (SNPs)   deposited   in   the   SNP   database  
(http://www.ncbi.nlm.nih.gov/projects/SNP).   A   small   portion   of   these   SNPs   are  
associated  with  inter-­individual  differences  in  the  expression  and/or  function  of  hFMO3  
enzyme  that  can  contribute  to  an  individual’s  susceptibility  to  toxicants  and  drug  response  
[6].  Mutants  may  affect  activity   towards  given  substrates  by  decreasing,   increasing  or  
even  totally  abolishing  it  [1-­8].    
The  most  common  hFMO3  genetic  variants  are  E158K,  V257M  and  E308G,  and  have  
been  shown  to  have  a  relatively  high  population  distribution  [7].  Cashman  and  colleagues  
demonstrated  a  frequency  of  V257M  polymorphism  among  African-­Americans  which  is  
8%   versus   a   frequency   of   20%   for   Asians   [7].   Similarly,   Lattard   and   colleagues  
demonstrated   a   higher   frequency   of   the   E308G   polymorphisms   in   Asians   and  
Caucasians,  while  the  E158K  is  found  at  a  higher  frequency  in  African-­Americans  and  
Caucasians   [9].   In   Europeans   and  Asians,   the   haplotype  E158K/E308G   is   present   in  
20.6%  of  individuals  [10]  and  has  been  shown  to  reduce  the  activity  of  the  enzyme  with  
different  substrates   including  methamphetamine,   tamoxifen,   thiacetazone  and  sulindac  
sulfide  [3].      
In  this  work,  the  metabolism  of  three  different  drugs  namely  tamoxifen,  clomiphene  and  
GSK5182   by   the   recombinant   wild-­type   (WT)   hFMO3   (Uniprot   Code:   P31513,   Gene  
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name:   FMO3_HUMAN)   and   its   three   common   polymorphic   variants   V257M   hFMO3  
(rs1736557,  Global  minor  allele  frequency  -­  GMAF  =  0.0976),  E158K  hFMO3  (rs2266782,  
GMAF  =  0.3478),  E308G  hFMO3  (rs2266780,  GMAF  =  0.0915)  was  investigated.  These  
three  compounds  are  at  present  used  for  the  treatment  of  different  diseases  but  share  the  
same  carbon  backbone  (Fig.  1):  tamoxifen  (a  breast  cancer  drug,  [11,  12]),  clomiphene  
(a  well-­known  drug  used   for   the   treatment   of   infertility   in  woman,   [13])   and  GSK5182  
(currently  being  evaluated  in  preclinical  studies  as  a  new  anti-­diabetic  agent  for  Diabetes  
mellitus  type  2,  [14]).  These  three  selected  drugs  have  been  reported  to  be  converted  to  
the  N-­oxide  product  by  WT  hFMO3  [11,12,15-­17]  but  differences  in  their  metabolism  due  
to  polymorphisms  have  not  been  reported  so  far.    
  
Materials  and  Methods  
Materials  
NADPH  was  purchased  from  Merck  Group,  Milan,  Italy.  Methanol  and  acetonitrile  were  
purchased  from  Appenlab,  Turin,  Italy.  Salts  and  tamoxifen  were  purchased  from  Sigma  
Aldrich,   Milan,   Italy.   Tamoxifen   N-­oxide   was   purchased   from   Toronto   Research  
Chemicals  Inc.,  New  York,  ON,  Canada.  Clomiphene,  clomiphene  N-­oxide  and  GSK5182  
were  purchased  from  D.B.A.  Italia  S.r.l,  Segrate,  Italy.  
  
Purification  of  Recombinant  Polymorphic  proteins    
The  common  polymorphic  variants  of  hFMO3  were  previously  prepared  in  our  lab  using  
the  QuikChange  site-­directed  mutagenesis  kit  (Stratagene,  USA)  [4,  8].    
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All  steps  of  expression  and  purification  were  performed  according  to  previously  published  
protocols  [18,  19].  WT  and  polymorphic  variants  were  expressed  in  E.  coli  JM109  and  
after  the  induction  with  IPTG  cells  were  furtherly  grown  for  24  hours.  The  proteins  were  
purified  using  negative  anionic  exchange  chromatography  (the  protein  is  not  retained  by  
the  DEAE   resin   at   pH   7.4)   and  Nickel   affinity   chromatography.   Spectra   of   the   eluted  
fractions   (with   40   mM   histidine)   were   obtained   using   a   diode   array   HP-­8453E  
spectrophotometer.  IGEPAL  at  a  concentration  of  0.1%  was  present  during  all  steps  of  
protein  purification  and  diluted  by  means  of  ultrafiltration  after  affinity  chromatography  till  
histidine  was  below  40  µM.  FAD-­containing  fractions  with   the  characteristic  absorption  
peaks   at   375   and   442   nm   were   pooled   and   exchanged   to   storage   buffer   (100   mM  
potassium  phosphate  buffer  pH  7.4,  20%  glycerol  and  1  mM  EDTA)  by  30  kDa  cutoff  
Amicon  membranes  and  stored  at  -­80  °C.    
  
Enzyme-­substrate  incubations    
Enzyme  incubations  were  performed  at  37  °C  using  1  mM  NADPH,  tamoxifen  (2.5  –  100  
µM)  or  clomiphene  (5  –  100  µM)  or  GSK5182  (0  –  80  µM)  in  200  µL  of  50  mM  KPi  pH  7.4.  
The  reactions  were   initiated  by  adding  0.64  µM  of   the  pure  enzyme  for   tamoxifen  and  
GSK5182  and  1  µM  for  clomiphene.  
  
Enzymatic  N-­oxide  products  analysed  by  HPLC      
In  all  cases,  rates  of  N-­oxygenation  of  the  3  substrates  were  calculated  by  quantifying  the  
product  using  a  4.6  x  150  mm  5  µm  Eclipse  XDB-­C18  column  mounted  on  an  Agilent  
1200  HPLC  system.      
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WT  and  polymorphic  variants  of  hFMO3  with  tamoxifen  
Tamoxifen   was   dissolved   in   ethanol   (solubility   10  mg/ml)   and   stored   at   4   °C   in   dark  
containers.  Tamoxifen  N-­oxide  was  dissolved  in  methanol  at  a  final  concentration  of  20  
mM  and   stored   at   -­20   °C.   The   enzymatic   reactions  were   carried   out   at   37   °C   for   10  
minutes  and  were  terminated  by  adding  100  µl  of  ice  cold  acetonitrile.  After  this  time,  the  
samples  were  spun  at  14,000  rpm  for  5  min  in  order  to  eliminate  the  precipitated  protein.  
A   100   µl   sample   of   each   resulting   supernatant  was   subsequently   analysed   by  HPLC  
according  to  the  previously  published  methods  [11,  17].  Reaction  mixtures  in  the  absence  
of  hFMO3,   tamoxifen  and/or  NADPH  were  used  as  controls  and   the  metabolites  were  
identified  by  comparison  with  commercially  available  synthetic  standards.    
  
WT  and  polymorphic  variants  of  hFMO3  with  clomiphene  
Solutions  of  clomiphene  and  clomiphene  N-­oxide  were  prepared  by  dissolving  the  powder  
in  methanol.  Incubations  with  the  enzyme  were  kept  at  37  °C  for  30  minutes  and  the  then  
terminated  by  the  addition  of  100  µL  of  ice-­cold  methanol.  Samples  were  spun  at  14,000  
rpm  for  5  min  to  eliminate  the  precipitated  protein  and  the  resulting  supernatants  were  
analysed  by  HPLC.  A  50  µl  sample  of  each  reaction  was  injected  in  the  HPLC  system  
and   the  separation  was  performed  according   to  previously  published  method   [15].  For  
clomiphene,   the   metabolites   were   identified   by   comparison   with   purchased   synthetic  
standards.  Reaction  mixtures  in  the  absence  of  FMO3  or  clomiphene  and/or  NADPH  were  
used  as  controls.    
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WT  and  polymorphic  variants  of  hFMO3  with  GSK5182  
Currently,  the  metabolite(s)  of  the  GSK5182  reaction  with  hFMO3  are  not  commercially  
available   and   therefore   the   expected   N-­oxide   product   was   confirmed   by   mass  
spectrometry  analysis  (see  next  section).  The  solution  of  GSK5182  N-­oxide  was  prepared  
enzymatically  by  incubating  the  substrate  with  the  pure  enzyme  at  37°C  for  3  hours  to  
reach  complete  conversion.  For  the  determination  of  the  Michaelis-­Menten  parameters,  
reactions  were  carried  out  at  37  °C  for  20  minutes  and  terminated  by  addition  of  100  µl  
acetonitrile.  Reactions  in  the  absence  of  hFMO3  or  GSK5182  and/or  NADPH  were  used  
as  controls.  GSK5182  and  its  product  were  separated  on  a  4.6  x  150  mm  5  µm  Eclipse  
XDB-­C18  column  at  room  temperature  and  with  the  UV-­  visible  detector  set  at  340  nm.  A  
30  µl  sample  of  was  injected  in  the  HPLC  system  and  the  separation  was  performed  using  
isocratic  elution  with  75%  of  acetonitrile  25%  of  0.1%  formic  acid  in  water.    
  
Mass  spectrometry  
The  identification  of  GSK5182  N-­oxide  product  was  carried  out  in  collaboration  with  Ion  
Source  &  Biotechnologies  Srl  (Milan,  Italy)  employing  a  SACI/ESI  source  coupled  to  an  
Orbitrap  mass  spectrometer  (ThermoFisher,  San  Jose,  USA)  working  in  positive  ion  mode  
[20].  Spectra  acquisition  was  performed  in  the  40–3500  m/z  range.  ESI  capillary  voltage  
was  kept  at  1500  V,  SACI  surface  voltage  was  set  to  47  V,  drying  gas:  2  L/min,  nebulizer  
gas:  80  psi  and  temperature:  40°C.  Fragment  and  precursor  ions  isolation  was  performed  
using  an  ion  trap  (isolation  windows  ±0.3  m/z,  collision  energy  30%  of  its  maximum  value  
(5  V  peak  to  peak)  and  the  Orbitrap  mass  analyser  was  used  to  obtain  the  fragments  at  
high  accurate  m/z  ratio  (resolution  15,000,  m/z  error  <10  ppm).    
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Results    
Tamoxifen,  clomiphene  and  GSK5182  were  incubated  with  the  purified  WT  hFMO3  and  
its   three  common  polymorphic  variants.  Recombinant  WT,  V257M,  E158K  and  E308G  
were  heterologously  expressed   in  E.   coli   and  purified  using   ion  exchange  and  affinity  
chromatography.  The  activity  of   the  enzymes  was  followed  by  performing  steady-­state  
kinetics   experiments  at   37°C   in   physiological   buffer   at   pH  7.4  with   the   three   selected  
compounds.   Michaelis-­Menten   parameters   were   determined   for   the   N-­oxygenation   of  
GSK5182,  tamoxifen  and  clomiphene,  and  the  data  are  shown  in  Figure  2.    
For  tamoxifen  and  clomiphene,  the  products  were  separated  and  identified  using  HPLC  
as  reported  in  the  Methods  and  materials  section.  However,  GSK5182  has  only  recently  
been  reported  to  be  metabolised  to   the  corresponding  N-­oxide  by  hFMO3  [16]  and  no  
standards  of  the  latter  product  are  commercially  available.  Therefore,  mass  spectrometry  
was  used  to  verify  the  conversion  of  this  compound  to  the  corresponding  N-­oxide  product  
by  the  purified  recombinant  hFMO3.  As  expected  GSK5182,  with  a  mass  of  418.3,  was  
indeed   converted  by   the  purified  enzyme   to  GSK5182  N-­oxide,  with   a  mass  of   434.3  
(Figure  3B).  Fragmentation  of  the  434.3  ion  yielded  2  different  ions:  252  and  182.0  that  
contains  the  N-­oxide  as  further  proof  of  the  in  vitro  enzymatic  catalysis  (Figure  3A,  B).      
Nonlinear   regression   analysis   of   the   data   obtained   allowed   for   the   calculation   of   the  
kinetic   parameters   for   the   three   variants   and   their   comparison   to  WT   (Table   1).  Data  
analysis  demonstrated  that  for  GSK5182,  the  kcat  value  of  V257M  variant  was  2.5  times  
higher  compared  to  that  of  the  WT,  whereas  both  E158K  and  E308G  variants  showed  
50%  decrease  in  activity  compared  to  the  WT  enzyme  (Table  1).  Overall,  there  were  no  
significant  differences  among  the  variants  for  the  GSK5182  affinity  to  the  enzymes,  as  
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can  be  seen  by  the  Km  values  that  are  between  4.5-­9.82  µM,  except  for  V257M  with  a  Km  
of   28.5  µM.  Although   the   turnover   numbers   calculated   for   the   three   variants  were   all  
significantly  different   to   that  of   the  WT  hFMO3,  overall  no  significant  differences  were  
observed  in  terms  of  kcat/Km  or  the  relative  clearance  of  GSK5182  as  reported  in  Table  1.    
For  tamoxifen,  the  calculated  kcat  values  of  the  three  polymorphic  variants  are  in  general  
2-­3  times  lower  than  those  of  the  WT  enzyme  (Table  1).  On  the  other  hand,  Km  values  
obtained   demonstrate   a   higher   affinity   for   tamoxifen   for   E158K   and   E308G   variants.  
Moreover,   both   kcat/Km   and   relative   clearance   are   affected   but   in   different  ways   in   the  
variants;;  significantly  decreased  for  V257M  but  significantly  increased  for  E158K  variant.  
In  this  case,  the  metabolism  is  both  variant-­  as  well  as  substrate-­dependent.    
The   enzymatic   N-­oxygenation   of   clomiphene   was   also   evaluated   and   the   kinetic  
parameters   compared   to   those   of   the  WT   hFMO3.   One   of   the   polymorphic   variants,  
E158K,  showed  no  significant  differences  compared  to  the  WT  enzyme  in  terms  of  the  
kinetic   parameters   calculated   i.e.   Km,   kcat   and   kcat/Km.   For   the   other   two   variants,   the  
turnover  numbers  for  clomiphene  were  increased  around  4  times  compared  to  the  WT  
enzyme  (Table  1).  These  two  variants  also  showed  a  significantly  lower  substrate  affinity.  
As  can  be  seen  in  Table  1,  both  kcat/Km  and  relative  clearance  are  significantly  impacted  
by   the  mutations:  E158K  shows   lower  clearance  whereas  the  other   two  variants  show  
markedly  increased  clearance,  more  than  tamoxifen  or  GSK5182.      
  
Discussion  
The  data  demonstrate   that  depending  on   the  specific  hFMO3  polymorphic   variant   the  
metabolism  of  the  three  structurally  similar  drugs  can  be  slightly  or  severely  affected  when  
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compared  to  the  WT  form  of  the  enzyme  (Table  1).  Therefore,  it  is  not  possible  to  predict  
the   protein   functionality   on   the   basis   of   the  mutation,   but   it   is   crucial   to   evaluate   the  
oxygenation  rates  for  each  specific  substrate  i.e.,  the  metabolic  capacity  of  the  variants  
is   substrate   dependent.  Nevertheless,   by   comparing  each   variant   to   the  WT  enzyme,  
E158K  seems   to  be   the  most  affected  as  shown  by   the  constant  decrease   in   the  kcat  
values  for  all  three  substrates  studied.  For  E308G  a  substantial  decrease  in  kcat  was  found  
for  tamoxifen  and  GSK5182  as  opposed  to  a  moderate  increase  for  clomiphene.  V257M  
showed   decreased   kcat   for   tamoxifen   and   increased   kcat   for   both   clomiphene   and  
GSK5182.    
To  explain  differences  in  drug  metabolism  rates  a  key  factor   is  the  identification  of  the  
location  of  the  mutations  in  the  structure  of  hFMO3  leading  to  a  possible  justification  for  
the   observed   functional   differences,   structure-­function   relationship.   Unfortunately,   at  
present  such  a  structure  is  lacking  and  therefore  we  can  only  rely  on  in  silico  homology  
models   (Figure  4)   [21,  22].  According   to   the   latter  3D  models,  E308   is   located  on   the  
surface  of  the  enzyme  in  the  NADP+  binding  domain  in  a  position  that  could  potentially  
affect  the  stability  and  correct  positioning  of  the  cofactor  in  the  active  site  [21,  22],  while  
E158  is  situated  in  a  putative  access  channel  to  the  catalytic  domain  near  the  NADPH  
binding  motif.  Finally,  V257  is  not  in  the  immediate  vicinity  of  the  active  site  and  is  part  of  
the  hFMO3  “insert”  region  in  a  loop  that  protrudes  from  the  NADP+  binding  domain  across  
the  FAD  binding  domain  [21].  We  have  recently  demonstrated  the  inactivation  mechanism  
of  hFMO3  by  a  SNP  in  the  active  site  of  the  enzyme  that  impairs  the  efficient  binding  of  
NADP+   [23].   This   current   work   demonstrates   how   even   surface   SNPs   in   the   NADP+  
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binding  domain  of  hFMO3  can  affect  its  ability  to  perform  catalysis  by  either  decreasing  
or  increasing  it.    
It   is   evident   from   the   analysis   of   the   location   of   the   mutations   (Figure   4),   that   this  
parameter  cannot  in  itself  justify  the  differences  in  the  activity  of  the  enzymes  in  relation  
to   the   different   substrates.   Moreover,   the   structural   and   activity   data   collectively  
demonstrate  that   it  cannot  be  affirmed  that  a  particular  polymorphic  variant  will  have  a  
lower/higher  activity  per  se.   Indeed,   the  metabolic  capacity   is  both  variant-­  as  well  as  
substrate-­dependent.    
In   conclusion,   this   work   highlights   the   importance   of   considering   common   genetic  
polymorphisms   of   the   hFMO3   gene   in   the   population   when   testing   new   drugs   or  
administering  already  approved  therapies  in  the  era  of  personalised  medicine.    
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Table  1  Kinetic  parameters  for  GSK5182,  Tamoxifen  and  Clomiphene  of  wild  type  and  3  




Variant   Km     kcat   kcat/Km  
Relative  
clearance  
	  	   	  	   µM	   	  min-­1	   min-­1µM-­1	   (%  of  wild  type)  
	  	                           
GSK	  5182	  
WT   9.82±1.85   2.22±0.22   0.22±0.048   100.00  
V257M   28.5±6.2*   5.69±0.47*   0.19±0.046   86.36  
E158K   4.57±0.42   1.16±0.05*   0.25±0.026   113.64  
E308G   5.87±0.92   1.20±0.08*   0.20±0.035   90.91  
	  	                           
Tamoxifen	  
WT   6.4±0.7   1.13±0.7   0.18±0.02   100.00  
V257M   8.1±0.5*   0.6±0.02*   0.07±0.005*   38.89  
E158K   1.56±0.03*   0.45±0.01*   0.29±0.01*   161.11  
E308G   2.50±0.3*   0.38±0.02*   0.15±0.02   83.33  
	  	                           
Clomiphene	  
WT   18.3±2.1   0.07±0.002   0.004±0.0005   100.00  
V257M   33.2±3.85*   0.30±0.01*   0.009±0.001*   225.00  
E158K   20.46±3.29   0.06±0.003   0.003±0.0005   75.00  
E308G   44.4±1.67*   0.25±0.01*   0.006±0.0003*   150.00  
*p	  <	  0.05	  versus	  wild-­‐type	  hFMO3	   	     
     





Fig.1   Chemical   structures   of   tamoxifen   analogues   used   in   this   study.   The   N-­
oxygenation  site  attacked  by  hFMO3  is  highlighted  in  red.  
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Figure  2    
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Fig.  2  Michaelis-­Menten  curves  of  the  enzymatic  activity  of  hFMO3.  Data  shown  for  
wild-­type   hFMO3   and   its   3   common   polymorphic   variants   in   the   presence   of   (A)  
GSK5182,  (B)  Tamoxifen  and  (C)  Clomiphene  (each  point  represents  the  mean  ±  SD  of  
three  parallel  experiments).  
  
  
     







Fig.3  Fragmentation  profile  of  GSK5182  N-­oxide.  Enzymatic  N-­oxide  product  with  the  
molecular  ion  434.2  (A)  and  subsequent  result  of  the  cleavage  of  253.0  and  182.0  in  MS  
(B).    
  


















Fig.  4    
Structural  model  of  hFMO3   [22].  NADP-­binding  domain  is  shown  in  green  with  FAD-­
binding  domain  in  red.  The  insert  region  is  colored  in  blue.  The  FAD  molecule  is  shown  
in  yellow  sticks  together  with  the  3  mutation  sites:  V257  in  orange,  E158  in  magenta  and  
E308  in  cyan.  
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